Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Vitamin D: a natural inhibitor of multiple sclerosis.
Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica.
Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.
Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature.
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Neuroprotective effects of riluzole in neurotrauma models: a review.
Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.
The site of production of superoxide radical in mitochondrial Complex I is not a bound ubisemiquinone but presumably iron-sulfur cluster N2.
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
CD46: The 'multitasker' of complement proteins.
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
A qualitative exploration of the impact of a 12-week group exercise class for those moderately affected with multiple sclerosis.
Frequent but nonspecific venous narrowing in paediatric multiple sclerosis.
European medicines agency's committee for medicinal products for human use issues positive opinion on marketing authorisation application for Fampyra
A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q).
Alemtuzumab (Lemtrada) - NICE says yes in final draft guidance
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
Monosymptomatic clinically isolated syndrome with sudden sensorineural hearing loss: case report and critical review of the literature.
Concurrent saturation transfer contrast in in vivo brain by a uniform magnetization transfer MRI.
The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.
Cytokines and Disability in Interferon-β-1b Treated and Untreated Women with Multiple Sclerosis.
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.

Pages